Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now


  •   Email
  •   Print
  •   Share
  • Dana-Farber Blog

    • Insight Blog screenshot Insight features the latest in cancer care and research news from Dana-Farber.
    • Read the blog 
  • Dana-Farber Facts

    • cover of the Dana-Farber 2017 Facts brochureFind statistics on Dana-Farber's patient care, fundraising initiatives and achievements, and phone numbers for patients and families.
    • View Dana-Farber Facts
  • More than Courage

    • More than Courage coverLearn more about Dana-Farber and the Jimmy Fund's courageous care, innovation, and commitment to beating cancer.
    • View More than Courage
  • The Cancer Treatment Revolution

    • The Cancer Treatment Revolution book cover Dr. David Nathan, acclaimed pediatric hematologist and Dana-Farber's president from 1995 – 2000, recounts that history's triumphs and struggles in his book, The Cancer Treatment Revolution.

Dana-Farber Spotlight

Sign up to receive Dana-Farber Spotlight, our email newsletter.
View the current issue
Subscribe now
Unsubscribe from mailings

Media Contacts

Ellen Berlin
Director of Media Relations

Molly McHale
Associate Director of Media Relations


Top News Releases

Leigh Ellis, PhD
  • September 12, 2017
  • New biomarker predicts metastatic prostate cancers
  • In a new study, published online by Clinical Cancer Research, Dana-Farber scientists have found a genetic signature within prostate cancer cells that they say can predict which tumors are likely to metastasize.
F. Stephen Hodi, MD
  • September 11, 2017
  • Immunotherapy combination improves survival in advanced melanoma
  • The first three-year survival data from a clinical trial of combination immunotherapy for patients with advanced melanoma continues to show a marked advantage for treatment with nivolumab, a PD-1 checkpoint blocker, compared with the CTLA-4 checkpoint blocker ipilimumab.
Lewis Silverman, MD
John Quackenbush, PhD
  • August 29, 2017
  • Study reveals genetic networks that influence complex human traits
  • Scientists at Dana-Farber Cancer Institute say they have made an important step toward understanding how variations in the human genetic blueprint determine complex traits such as normal body functions and susceptibility to cancer and other diseases.

Dana Farber In the News


    Image Alt Text
    Image Alt Text
    Image Alt Text